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Using PCR-SSCP/DNA sequencing methods, we analyzed
14 oral squamous-cell carcinomas (OSCCs) and 8 pre-
malignant oral lesions from different Sudanese patients for
prevalence of mutations in exons 5 to 9 of the p53 gene in
relation to toombak-dipping status. OSCCs (14 from Sudan,
28 from Scandinavia), and 3 pre-malignant oral lesions from
Sudanese non-dippers were used as controls. A statistically
significant increased incidence in mutations of the p53 gene
was found in OSCCs from toombak dippers (93%; 13/14), as
compared with those from non-dippers in Sudan (57%; 8/14)
and in Scandinavia (61%; 17/28) respectively. In OSCCs from
dippers, mutations were found in exons 5 to 9, while in those
from non-dippers they were found in exons 5, 7, 8, 9, and no
mutations were found in exon 8 in any of the OSCCs from
Sudan. Certain types of mutations, however, were similar
with respect to exposure to toombak. OSCCs from dippers
showed 15 transversions, 9 transitions, 3 insertions and one
deletion, compared with 7 transversions, 2 transitions and
one deletion found in OSCCs from Sudanese non-dippers,
and 9 transversions, 17 transitions and 2 insertions found in
those from non-dippers in Scandinavia. No mutations were
found in any of the non-malignant oral lesions in relation to
dipping or non-dipping status. These findings suggest that (i)
the use of toombak plays a significant role in induction of
increased p53 gene mutations, (ii) mutations observed were
similar to those induced by tobacco-specific N-nitrosamines
(TSNAs) in experimental animal models and those already
reported in toombak dippers, (iii) types of mutations associ-
ated with TSNAs were similar in the exposed and the control
groups, (iv) a novel mutation in exon 6 was found in the
OSCCs from toombak dippers, (v) the p53 exons 5 (codon
130), 6 (codons 190, 216) and 7 (codons 229, 249, 252)
mutations are probable hot spots for toombak-related OS-
CCs. Further studies are necessary to validate the increased
incidence and exon locations of the p53-gene mutations as a
biomarker of malignant transformation in populations in
which the oral use of tobacco is habitual. Int. J. Cancer
81:527–534, 1999.
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Globally, the incidence of oral squamous-cell carcinomas
(OSCCs) is on the increase, especially in developing countries,
where oral-health-care resources are meagre (Johnson, 1991). The
most frequently mutated tumor-associated gene yet identified is the
p53 gene found in mutated form in more than 50% of all human
tumors (Hollstein et al., 1991). In OSCCs, 98% of p53-gene
mutations have been described in exons 5 to 8, in codons 238–248
(exon 7) and 278–281 (exon 8); and these DNA regions are likely
hot spot areas (reviewed in Raybaud-Dioge`ne et al., 1996). These
mutations have been found to show variations in different countries
in relation to geographical location as well as ethnicity (Greenblatt
et al., 1994; Raybaud-Dioge`ne et al., 1996). For example, in the
USA most mutations were detected in exon 7, while in Sweden and
Japan they were detected in exon 8 (Greenblatt et al., 1994;
Raybaud-Dioge`ne et al., 1996). Several reports have investigated
the association between p53 expression and gene mutation in
OSCCs from patients with habits of oral use of tobacco and/or
alcohol drinking. p53-protein over-expression has been shown to
positively correlate with patient history of cigarette smoking and
alcohol drinking (Field et al., 1991, 1994; Brennan et al., 1995;
Lazarus et al., 1996b), betel-nut and tobacco chewing (Kaur et al.,
1994) and toombak dipping in Sudan (Lazarus et al., 1996a).
Toombak is a form of oral snuff extensively used in Sudan (Idris et
al., 1995). In OSCCs, it has been illustrated that there is a wide
spectrum of p53-gene mutations in cigarette smokers who also
consume large quantities of alcohol, predominately at the cytidine-
phosphate-guanosine (CpG) sites. These sites have been suggested
as endogenous mutational ‘‘hot spots,’’ for those who do not smoke
cigarettes or drink alcohol (Brennan et al., 1995). p53-gene
mutations have been reported from 2 OSCCs from toombak
dippers, one at codon 285 (CGGarg = TGGtrp) and the other in
intron 6 (AT = GC), while no mutations were found in an OSCC
from a non-dipper (Lazarus et al., 1996a). The tobacco-specific
nitrosamines (TSNAs), present at inordinately high levels in
Sudanese toombak, are believed to play an integral role in the
development of tobacco-related OSCCs in Sudan (Idris et al.,
1995; Lazarus et al., 1996a).
We have reported a significantly lower relative frequency of
p53-protein expression in OSCCs from toombak-dippers compared
with those from non-dippers in Sudan and Scandinavia (Ibrahim et
al., 1996). Although the early protein 6 (E6) of the high-risk
human-papilloma-virus (HPV) types has been shown to induce
degradation of the p53 protein (Scheffner et al., 1990), we could
not detect the HPV genome in OSCCs from toombak-dippers or
non-dippers (Ibrahim et al., 1998). In contrast, a significantly
higher level of expression of keratin 13, 14 and 19 was found in the
same OSCCs from Sudanese toombak dippers than in those from
non-dippers in Sudan and in Scandinavia (Ibrahim et al., 1998).
Epidemiological studies from Sudan have suggested a causal
relationship between oral use of toombak and the development of
OSCCs (Idris et al., 1995). In Scandinavia, however, the relation
between the oral use of snuff and the development of OSCCs is
subject to controversy (Socialstyrelsen, 1996). Since the p53
tumor-suppressor gene is a likely candidate for toombak-induced
genetic alterations, the objective of the present study was to
determine the prevalence of p53 point mutations in the OSCCs and
non-malignant oral lesions from Sudan already studied (Ibrahim et
al., 1996), together with control OSCCs and non-malignant oral
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lesions from non-dippers in Sudan and Scandinavia used in our
earlier studies (Ibrahim et al., 1996, 1998). Polymerase-chain-
reaction-single-strand-conformation-polymorphism (PCR-SSCP)
and DNA-sequencing techniques were used for molecular analysis,
and the findings were correlated with the habitual oral use of snuff.
MATERIAL AND METHODS
Oral tissue samples
Formalin-fixed, paraffin-embedded tissue specimens of OSCCs
(n 5 14) and of non-malignant oral lesions (n 5 8) from individual
Sudanese toombak dippers, and OSCCs (n 5 14) and non-malignant
oral lesions (n 5 3) from individual Sudanese non-dippers de-
scribed earlier (Ibrahim et al., 1996), were included in the present
work. No data on current or previous history of cigarette smoking
were available for any of the patients selected from Sudan. As
controls, 28 formalin-fixed, paraffin-embedded tissue specimens of
OSCCs from non-dippers in Scandinavia (17 in Norway 11 in Sweden)
were included, as have been described earlier (Ibrahim et al., 1996). Of
the Scandinavian controls, 11 Norwegian patients (all males) and 8
Swedish patients (6 males, 2 females) reported cigarette smoking,
with no information on the number of cigarettes smoked daily or
weekly. No data on alcohol consumption were available.
DNA extraction
From the paraffin blocks, 2 or 3 10-µm-thick sections were cut,
and total cellular DNA was extracted following the procedures
described by Wright and Manos (1990) and Wang et al. (1994) with
slight modifications. After repeated steps of de-waxing in xylene,
centrifuging and re-suspending in absolute ethanol, the formed
pellet was dried at 37°C overnight, re-suspended in 100 µl of
digestion buffer (50 mM Tris-HCl, pH 8.5, 1 mM EDTA and 0.5%
Tween) containing 200 µg/ml of proteinase K (Sigma, St. Louis,
MO) and incubated at 37°C for 5 days. Fresh enzyme was added
each day, the final volume being 210 µl. Thereafter, an equal
volume of 20% Chelex-100 (BioRad, Hercules, CA) solution
containing 0.1% SDS and 1% Tween 20 was added. For recovery of
DNA, the mixture was incubated at 37°C for 30 min, boiled at 95°C
for 8 min, centrifuged at 12,000 g for 1 min; thereafter the
supernatant was carefully collected into a fresh tube. DNA was
quantified using a spectrophotometer (Beckman, DU 530, Life
Sciences, Fullerton, CA).
Polymerase chain reaction and single-strand conformation
polymorphism (PCR-SSCP)
A two-round nested PCR protocol was used. For the first
PCR-round, exons 5 to 9 of the p53 gene were amplified in vitro
from each sample using primers described by Ryberg et al. (1994),
as shown in Table I. Primers were obtained from (MedProbe, Oslo,
Norway). The PCR was carried out in the GeneAmp PCR System
9700 (Applied Biosystems, Foster City, CA). In this round of PCR
amplification, the 50-µl PCR reaction mixture consisted of 1 µl of
the genomic DNA solution, 200 µM of each of the 4 deoxynucleo-
tide triphosphates (dNTPs), 0.25 U AmpliTaq Gold DNA polymer-
ase (5 U/µl, Applied Biosystems), 1.25 (for primer exon 5), 1 (for
primer exons 6 and 7) and 2.5 (for primer exons 8/9) mM MgCl2
respectively, and 10 pmol of each of the primers. A ‘‘hot start’’ at
94°C for 10 min was followed by 40 cycles of amplification, where
each cycle consisted of 40 sec de-naturation at 94°C, 1 min
annealing at 55°C, and 1 min extension at 72°C. The last PCR cycle
was followed by a final extension at 72°C for 7 min. PCR reactions
without DNA as a template were used as negative controls. Human
placental DNA was used as normal control. Determination of the
PCR amplification product was done by electrophoresis and
staining with 0.5 µg/ml ethidium bromide in a 3% agarose gel; the
amplified samples were recorded. Therafter, from the PCR prod-
ucts, 0.1 µl for the amplified samples and 1 µl for the non-amplified
ones were re-amplified with the second round primers (obtained
from MedProbe) described by Gaidano et al. (1991), as shown in
Table I. All the conditions were the same as for the first round PCR,
except that 2 mM MgCl2 was used with all the primers, applying
0.25 U of the enzyme AmpliTaq DNA polymerase (5 U/µl, Applied
Biosystems). Determination of this second-round PCR amplifica-
tion product was done as for the first-round PCR, and the amplified
samples were recorded. Before the SSCP and DNA-sequencing
analysis of the amplified samples, second-round PCR products
were purified, either by the QIAquick Gel Extraction Kit or by the
QIAquick PCR Purification Kit, with use of a microcentrifuge as
described in QIAquick Spin Handbook (QIAquick, QIAvac; Qia-
gen, Chatsworth, CA).
For the SSCP analysis, 3 µl of the purified PCR products were
mixed with an equal volume of double-distilled water, and the
mixture was heated for 5 min at 95°C to de-nature DNA, rapidly
cooled on ice for a few min, then 1.4 µl of the mixture was directly
pipetted onto the PhastGel Sample Applicator 8/1 µl (Pharmacia,
Uppsala, Sweden), immediately followed by loading onto a gel.
Electrophoresis was carried out using the semi-automated electro-
phoresis system (PhastSystem) on polyacrylamide-gel electropho-
resis (PAGE), where 20% homogenous native gels were employed
at 4°C for exons 5, 6 and 9 with samples separated for 400, 500 and
600 Vh, respectively, and at 15°C for exon 7 and at 20°C for exon 8
with samples separated for 450 and 270 Vh respectively. DNA
bands were visualized with silver staining (PhastGel DNA silver-
TABLE I – FIRST- AND SECOND-ROUND PCR PRIMERS
Exon Product length(nts) Sequence
First-round PCR primers
5 299 58TTC AAC TCT GTC TCC TTC CT-38
58GCA ATC AGT GAG GAA TCA GA-38
6 224 58TGG TTG CCC AGG GTC CCC AG-38
58TGG AGG GCC ACT GAC AAC CA-38
7 718 58AGG CGC ACT GGC CTC ATC TT-38
58AGG GGT CAG CGG CAA GCA GA-38
8 and 9 445 58TTG GGA GTA GAT GGA GCC T-38
58AGT GTT AGA CTG GAA ACT TT-38
Second-round PCR primers
5 245 58TTC CTC TTC CTG CAG TAC TC-38
58ACC CTG GGC AAC CAG CCC TGT-38
6 189 58ACA GGG CTG GTT GCC CAG GGT-38
58AGT TGC AAA CCA GAC CTC AG-38
7 188 58GTG TTG TCT CCT AGG TTG GC-38
58GTC AGA GGC AAG CAG AGG CT-38
8 213 58TAT CCT GAG TAG TGG TAA TC-38
58AAG TGA ATC TGA GGC ATA AC-38
9 131 58GCA GTT ATG CCT CAG ATT CAC-38
58AAG ACT TAG TAC CTG AAG GGT-3
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TABLE II – MUTATIONS OF THE p53 GENE (EXONS 5–9) IN ORAL SQUAMOUS-CELL CARCINOMAS FROM SUDANESE TOOMBAK-DIPPERS AND FROM NON-DIPPERS IN SUDAN AND SCANDINAVIA
Exon 5 Exon 6 Exon 7 Exon 8 Exon 9
Tumor
number Codon/mutation
Tumor
number Codon/mutation
Tumor
number Codon/mutation
Tumor
number Codon/mutation
Tumor
number Codon/mutation
Sudanese 1/2 130/CTC = CTT (S) 3 190/CCT = CCG* (S) 2 229/TGT = TGG* 8/12 299/CTG = CTTG (1) 12 310/AAC = TTG*
Toombak-dippers 305/AAG = TAA* (stop)
(n 5 13/14) 1 166/TCA = GCA* 5 216/GTG = GGG* 6 229/TGT = TA (2) 3/11 310/AAC = ACC*
3 132/AAG = ATG* 7 237/ATG = ATA 13 312/ACC = AGC*
133/ATG = GATG (1) 8 239/AAC = TAA* (stop)
148/GAT = TGA* (stop)
4 139/AAG = GAG 3 242/TGC = TAC
142/CCT = CTT 9/3 249/AGG = AAG
10 245/GGC = GAA
11/2 252/CTC = CAC*
Non-snuff-dippers
Sudanese 14/15 132/AAG = ATG* 16 240/AGT = CCC* 20 322/CCA = CGA
(n 5 8/14) 249/AGG = AAG 323/CTG = CG (2)
17/18 244/GGC = TGA* (stop) 21 323/CTG = GGG*
19 254/ATC = GTC
Scandinavian 22/23 130/CTC = CTT (S) 26 238/TGT = CGT 26 279/GGG = GAG 36 308/CTG = CTA
(n 5 17/28) 315/TCT = TGT*
24 136/CAA = CCA* 26/27/28 246/ATG = ATA 33 281/GAC = GCC*
25 146/TGG = TAG (stop) 26/27 248/CGG = CGA 32/34 299/CTG = CTTG (1) 27 308/CTG = CTC* (S)
305/AAG = TAA* (stop)
28 248/CGG = CAA 35 306/CGA = TGA (stop) 33 309/CCC = TCC
29 244/GGC = GAA 323/CTG = CGG*
30 239/AAC = ACC* 30 322/CCA = CGA*
31 246/ATG = ATA
32 249/AGG = AAG
(S), silent mutation; *Transversion; (I), insertion leading to frameshift and stop codon; (2), deletion. All other mutations were transitions. Only tumors 5, 14–16, 19–21, 23–25, and 30–35 were
previously found positive for p53 protein expression by immunohistochemistry.
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staining kit). Under all the SSCP runnings, purified PCR products
of human placental DNA were included and processed under the
same conditions.
DNA sequencing
After the initial PCR/SSCP analysis of all the samples was
completed, a non-radioactive cyclic sequencing reaction was
performed for the samples to be sequenced using the manufactur-
er’s protocol for the ABI PRISM BigDye Cycle Sequencing Ready
Reaction Kit (Applied Biosystems). In the 10-µl amplification
reaction, 2 µl of the purified PCR products of the fragments which
showed mobility shifts in the SSCP analysis, 4 µl from the BigDye
reaction mixture, and 1.5 pmol from the PCR primers of the second
round PCR were amplified. Sequencing was done on the automated
ABI PRISM 377 DNA Sequencer (Applied Biosystems), and was
carried out in both directions to confirm the findings. The software
packages Vector NTI 5.1 and Align X 1.0 (InforMax BioSuite),
Version 5.0 for Windows (InforMax, North Bethesda, MD) were
used to analyze results of sequencing.
Statistical analysis
The 2-tailed Fischer’s exact test (at p , 0.05 significance level)
was used to compare analysis of p53 mutations in the OSCCs from
the Sudan and from Scandinavia. p53 mutations were correlated
with snuff dipping and/or cigarette smoking.
RESULTS
PCR and SSCP analysis for p53 mutations
For the 2-round nested PCR protocol, a prominent increase in the
total number of samples amplified was seen after the second-round
PCR. All samples that amplified with this round were subjected to
further analysis. For the PCR-SSCP analysis, sample DNA frag-
ments showing mobility shifts in comparison with those of normal
cellular DNA were sequenced. Amplified DNA showing only
mutant bands was used directly for sequencing.
Determination of the mutated sequences
A summary of the mutations (transitions, transversions, inser-
tions and/or deletions) of the p53 gene detected from the OSCCs
from toombak dippers and in those from non-dippers in Sudan and
Scandinavia is shown in Table II. There were no mutations detected
in samples from the non-malignant oral lesions from toombak
dippers or non-dippers in Sudan. Figure 1a (exon 7; from a
carcinoma from a Sudanese toombak dipper) and Figure 1b (exon
8; from a carcinoma from a non-dipper), present examples of the
band shifts found in the PCR-SSCP analysis for a tumor DNA with
no band shifts in the normal placental DNA (i), and the sequencing
results for both normal placental DNA (ii) and tumor DNA (iii). Of
the 14 OSCCs investigated from toombak dippers, mutations in
exons 5 to 9 were found in 93% (13/14), compared with 57% (8/14)
and 61% (17/28) in those from non-dippers in Sudan and in
Scandinavia respectively. In Figure 2, the association of toombak
dipping and/or non-dipping with the relative frequencies of muta-
tions of the p53 gene found in the OSCCs from toombak dippers in
Sudan compared with those from non-dippers in Sudan and/or
Scandinavia is shown. For the OSCCs from toombak dippers, the
mutations were found distributed in exons 5 (4 tumors; 29%), 6 (2
tumors; 14%), 7 (8 tumors; 57%), 8 (2 tumors; 14%) and 9 (4
tumors; 29%), while for those from non-dippers in Sudan and
Scandinavia, mutations were found distributed in exons 5 (6
tumors; 14%), 7 (11 tumors; 26%), 8 (5 tumors; 12%; only in the
Scandinavian OSCCs) and 9 (6 tumors; 14%) (Table II).
The difference in mutations of the p53 gene was statistically
significant in the OSCCs from Sudanese toombak dippers when
compared either with those from non-dippers in Sudan and in
Scandinavia ( p 5 0.04) or only with those in Scandinavia
( p 5 0.02). The difference in p53-gene mutations in the OSCCs
from non-dippers in Sudan and in Scandinavia was not statistically
significant ( p 5 0.91). In addition, no statistically significant
difference was found in p53 mutations for the OSCCs from
toombak dippers/non-dippers from Sudan ( p 5 0.07).
Relationship between p53 mutations and toombak dipping
The p53-gene-mutated OSCCs from toombak dippers (Table II)
showed 15 transversions (5 A:T to T:A in exons 5, 7–9; 4 T:A to
G:C in exons 5, 6 and 7; 2 T:A to A:T in exon 7; 2 A:T to C:G and
one C:G to G:C in exon 9; and one G:C to T:A in exon 5) and 9
transitions (5 G:C to A:T in exon 7; 3 C:G to T:A and one A:T to
G:C in exon 5). There were 3 insertions of one base pair in exons 5
and 8 (resulting in frameshifts and stop codon), and deletion of one
base pair in exon 7 (Table II). In exon 5, 2 transition mutations were
silent, and one transversion resulted in a stop codon (Table II). In
exon 6, one transversion was a silent mutation, while 3 transversions
(one in exon 7, and 2 in exon 8) resulted in stop codons (Table II).
For the OSCCs from Sudanese and Scandinavian non-dippers
(Table II), there were 7 transversions (2 A:T to T:A in exon 5; 2 C:G
to G:C in exon 9; 2 G:C to T:A in exon 7; one A:T to C:G in exon
7), 2 transitions (G:C to A:T and A:T to G:C found in exon 7) and
deletion of one base pair in exon 9 for the Sudanese carcinomas, as
compared with 9 transversions (3 A:T to C:G in exon 5, 7 and 8; 2
C:G to G:C in exon 9; 2 A:T to T:A in exon 8; one G:C to C:G in
exon 9; one T:A to G:C in exon 9), 17 transitions (12 G:C to A:T in
exons 5, 7–9; 4 C:G to T:A in exons 5, 8 and 9; one T:A to C:G in
exon 7) and 2 insertions of one base pair (resulting in frameshifts
and stop codon) in exon 8 for the Scandinavian OSCCs (Table II).
For the Sudanese OSCCs, one transversion in exon 7 resulted in a
stop codon, while for the Scandinavian ones, 2 transitions were
silent and one resulted in a stop codon in exon 5, one transition and
one transversion in exon 8 resulted in stop codons, and one
transversion in exon 9 was silent. Figure 3 shows a correlation
between the percentage of the total number of mutations (transitions/
transversions) found in the OSCCs from Sudanese toombak
dippers in comparison with those found in the OSCCs from
non-dippers in Sudan and Scandinavia. The mutations G:C to A:T,
C:G to T:A and G:C to T:A, known to be associated with TSNAs,
were found to be the most common in the OSCCs from toombak
dippers. However, this was not found to be different from those
observed in the OSCCs from non-dippers (Figure 3).
DISCUSSION
In the present work, a significantly higher incidence ( p 5 0.04;
p 5 0.02) of p53-gene mutations was found in OSCCs from
Sudanese toombak dippers than in those from non-dippers in Sudan
and Scandinavia together, and those in Scandinavia alone. Our
results show that exon locations of the p53-gene mutations were
related to exposure to toombak. These findings indicate that
toombak use plays an important role in inducing increased
incidence of p53-gene mutations with a wide spectrum of exons in
OSCCs from toombak dippers. We found that the exon numbers
and locations, but not the types of p53-gene mutations, differed in
relation to exposure to toombak. In the OSCCs from toombak
dippers, mutations were found in exons 5 to 9, while in those from
non-dippers they were found in exons 5, 7, 8 and 9. However, no
mutations were found in exon 8 in any of the OSCCs from
non-dippers in Sudan. The types of mutations seen, in relation to
those found in TSNAs in experimental animal models, were similar
in toombak users and in the control groups from non-users in
Sudan.
The most common types of mutations found in squamous-cell
carcinoma of the head and neck are C:G to T:A transitions. These
mutations are the second most common, after the G:C to T:A
transversions found in cigarette-smoking-related lung tumor (Green-
blatt et al., 1994). G:C to T:A, non-CpG G:C to A:T, and A:T to
G:C substitutions are known to be associated with tumors induced
by smokeless tobacco, particularly N-nitrosamines, in experimental
animal models (Greenblatt et al., 1994). C:G to T:A transitions are
the most common mutations observed in lung adenocarcinoma in
rodents treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-buta-
none) (NNK) (Belinsky et al., 1991; Oreffo et al., 1993). In
addition, G:C to T:A transitions are attributed to NNK in experimen-
tal animal models (Ronai et al., 1993). These mutation types are
similar to those we observed in the OSCCs from Sudanese toombak
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dippers (Table II), indicating that the increased incidence of
mutations of these types are probably related to N-nitrosamines in
tobacco (Belinsky et al., 1991; Oreffo et al., 1993; Greenblatt et al.,
1994). The possible role of TSNAs in the etiology of OSCCs in
toombak dippers, through induction of p53-gene mutations, has
been reported (Lazarus et al., 1996a). Thus, our findings appear to
support the suggested role of TSNAs, in particular the NNK, in
induction of mutations in human tumors (Belinsky et al., 1991;
Oreffo et al., 1993; Ronai et al., 1993). It is therefore probable that
TSNAs are involved in the etiology of OSCCs from Sudanese
toombak dippers, through induction of p53-gene mutations (Laza-
rus et al., 1996a).
It has been suggested that the TSNAs, particularly N-
nitrosonornicotine (NNN) and NNK, are major contributors in the
development of aerodigestive-tract tumors in tobacco chewers and
snuff dippers (Hoffmann and Hecht, 1985). Total levels of NNN
and NNK in cigarette smoke were found to be 2 to 10 times that of
benzo[a]pyrene (BaP) (Adams et al., 1987), and up to 1000 times
that found in moist and dry North American snuff (Hoffmann et al.,
1987). NNN and NNK are the only tobacco constituents known to
induce oral-cavity tumors in experimental animals (Hecht et al.,
1986). These findings strongly support the suggested role of NNN
and NNK as causative agents in TSNA-related carcinogenesis
(Brunnemann and Hoffmann, 1992). The Sudanese toombak has
been found to contain exceptionally high levels of both, up to
560-fold higher than those reported in North American or European
smokeless tobacco products (Idris et al., 1991). According to these
FIGURE 2 – The association of p53-gene mutations found with toombak
dipping and non-dipping in oral carcinomas from Sudan and Scandinavia.
FIGURE 1 – An example of PCR-SSCP and sequence analysis of tumor DNA (T) and normal DNA (N) for exon 7 (a) in a carcinoma from a
Sudanese toombak dipper) and for exon 8 (b) in a carcinoma from a non-dipper). (i) PCR-SSCP analysis illustrating mobility shifts found in T
DNA (indicated by arrows) in comparison with that found in N DNA after sequencing. ABI PRISM electrophotograms of N DNA (ii) and T DNA
(iii) are shown in 38–58 (anti-sense) directions. Multiple alignments of the 2 mutations have shown G-to-T transitions Arg-Lys (codon 249), and
Gly-Glu (codon 279), respectively, for the 2 tumor DNA samples analyzed.
531p53 MUTATIONS AND SNUFF DIPPING
observations, our findings of p53-gene mutations in the OSCCs
from toombak dippers appear to confirm that NNN and/or NNK are
strong human carcinogens. Thus, toombak use plays an important
role in inducing p53-gene mutations with a wide spectrum of exons
involved in OSCCs from toombak dippers. The differences in the
spectrum and profile of the p53-gene mutations found in OSCCs
from toombak dippers may also be attributed to the high levels of
TSNAs found in toombak (Idris et al., 1991). The high levels of
NNN and of NNK found in toombak probably explain the
increased incidence as well as the spectrum of mutational profile of
the p53 gene found in the OSCCs from Sudanese toombak-dippers
as compared with those from non-dippers in Sudan and in
Scandinavia.
In the present study, OSCCs from Sudanese non-toombak-
dippers showed 2 G:C to T:A transversions, one G:C to A:T, and
one A:T to G:C transitions. These findings are similar to those
found in OSCCs from toombak dippers. OSCCs from Scandina-
vian non-dippers showed 12 G:C to A:T and 4 C:G to T:A. For the
mutations observed in OSCCs from Sudanese non-dippers, there
were 2 G:C to T:A transversions found at the CpG sites (codon
244), one non-CpG G:C to A:T (codon 240) and one A:T to G:C
(codon 254), compared with 4 CpG G:C to A:T (at the hot spots of
exon 7; codons 244, 248), and 6 mutations at the non-CpG G:C to
A:T in the Scandinavian ones. In Western countries, the 2 major
risk factors for the development of OSCCs are the use of tobacco
and the consumption of alcohol (Johnson, 1991). In the OSCCs
from Scandinavian non-dippers, 19 patients reported cigarette
smoking, with no information on the amount smoked daily or
weekly. The spectrum of p53-gene mutations found in OSCCs from
cigarette smokers in Scandinavia is similar to that found in
tobacco-related lung tumor and OSCCs (Greenblatt et al., 1994). In
addition, the spectrum of p53-gene mutations is in agreement with
other studies on OSCCs reported from Europe and USA (Field et
al., 1991; 1994; Brennan et al., 1995; Lazarus et al., 1996b).
Alcohol drinking is traditionally not considered a risk for the
development of OSCCs in the Sudanese population (predominantly
Muslim). Any similarities in the spectrum and profile of p53-gene
mutations found in OSCCs from Sudanese non-dippers to those
found in tobacco-related tumors in experimental animals and to
those found in OSCCs from toombak dippers are probably a result
of under-reported current or past history of cigarette smoking in the
population. The involvement of other chemicals, habitual oral
practices and/or environmental carcinogens, resulting in the ob-
served mutations, is also possible.
We found lower levels of p53 protein expression in the same
OSCCs from toombak dippers than in OSCCs from non-dippers in
Sudan and Scandinavia (Ibrahim et al., 1996). The present results
indicate that the p53 gene is mutated in these carcinomas.
Mutations found included frameshifts, deletions and stop codons.
These mutations would encode for a truncated p53 protein which
can be difficult to detect by immunohistochemistry (Brennan et al.,
1995; Lazarus et al., 1996b). The results of the present study
support the view that more sensitive methods, such as PCR and
sequencing of the gene, appear necessary to disclose p53 mutations
(Field et al., 1991; Sasano et al., 1992). Earlier, we found high
expression of keratin 13, 14 and 19 in the same OSCCs from
toombak-dippers (Ibrahim et al., 1998). Our present findings
support our earlier suggestion of cytoplasmic complexes between
p53 protein and the keratins investigated. The high frequency of
p53-gene mutations in the OSCCs from toombak dippers is also
consistent with the absence of HPV in these carcinomas (Ibrahim et
al., 1998). In the present study, no p53 mutations were found in
pre-malignant oral lesions from Sudanese toombak dippers and
non-dippers, compared to the p53 mutations found in the OSCCs
from toombak dippers and non-dippers. These data suggest that
mutations of the p53 gene play an integral role in the progression of
OSCCs.
FIGURE 3 – The pattern of p53-gene substitution mutations (transitions/transversions) found in the carcinomas from Sudanese toombak dippers
and in those from non-dippers in Sudan and Scandinavia, with no difference in the mutations known to be associated with TSNAs in toombak users
and in control groups in Sudan.
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Some of the OSCCs investigated in this study showed multiple
and silent mutations of the p53 gene, in line with other studies
(Kanjilal et al., 1993, 1995). It has been suggested that multiple and
silent mutations in the p53 gene indicate that a special hypermutabil-
ity process operates on the gene during the generation of tumors
(Strauss, 1997). UV-induced murine skin tumors showed heteroge-
neity of p53 mutations within individual samples, suggesting that
these mutations may arise as a result of continuous exposure to
environmental carcinogens (Kanjilal et al., 1993). Multiple hetero-
geneous mutations may be detected by isolating individual mutant
alleles from PCR products and cloning them into suitable vectors
before sequencing. However, direct sequencing of the PCR prod-
ucts (Kanjilal et al., 1995) may miss these mutations. We main-
tained stringent conditions during the two-round-PCR amplifica-
tions. No mutations were found in normal control and placental
DNA or in the non-malignant oral-tissue specimens from Sudanese
toombak dippers or non-dippers. The multiple mutations found in
our study suggest a multicellular origin of the tumors examined, or
that these mutations are due to continuous exposure to environmen-
tal carcinogens found in tobacco.
In conclusion, our results indicate that (i) toombak use plays a
significant role in the induction of increased p53-gene mutations
with a wide spectrum of exons involved, including exon 6, thus
enhancing tumorigenesis of OSCCs among toombak dippers, (ii)
the types of mutations observed were similar to those induced by
TSNAs in rats and to those reported earlier in toombak dippers, (iii)
there is no difference in the incidence of certain types of mutations
associated with TSNAs found in the exposed and the control
groups, (iv) a novel mutation in exon 6 was found in the OSCCs
from toombak dippers, (v) mutation of exons 5 (codon 130), 6
(codons 190 and 216) and 7 (codons 229, 249 and 252) suggest that
these are probable hot spots for TSNA-induced tumors in humans.
In view of the similarities in the spectrum of mutations, the
significant differences in the type and number of exons involved by
mutations in the 2 populations may be explained by differences in
the type of exposure rather than by the ethnic origin of patients.
Further studies are needed to validate the p53 gene as a biomarker
of tobacco-induced tumor in humans, while differences in environ-
mental exposures or inherited characteristics between the 2 popula-
tions, require detailed investigation.
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